Syndax Pharmaceuticals

SNDX · NASDAQ

$13.25+$0.16 (+1.22%)TodayMarket closed · Oct 20, 7:33 PM ET

Prev close $13.09

Latest news

Press releaseOct 17, 9:22 PM ETBusiness Wire
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Press releaseOct 15, 4:01 PM ETGlobe Newswire
Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
Press releaseOct 13, 10:17 PM ETPRNewswire
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
NewsOct 13, 12:24 PM ETVandana Singh
Syndax Pharmaceuticals Suffers Pipeline Blow
NewsOct 13, 12:03 PM ETAvi Kapoor
Crude Oil Edges Higher; Citigroup Earnings Top Views
NewsOct 13, 8:02 AM ETAvi Kapoor
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
NewsOct 13, 6:28 AM ETAvi Kapoor
Why UnitedHealth Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Press releaseOct 12, 4:01 PM ETGlobe Newswire
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
Press releaseAug 4, 4:01 PM ETGlobe Newswire
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseJul 28, 7:00 AM ETGlobe Newswire
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
Press releaseJul 14, 8:00 AM ETGlobe Newswire
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
Press releaseJun 11, 7:03 AM ETGlobe Newswire
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Press releaseJun 11, 7:00 AM ETGlobe Newswire
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
Press releaseJun 2, 4:01 PM ETGlobe Newswire
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Press releaseMay 21, 5:01 PM ETGlobe Newswire
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
Press releaseMay 12, 10:31 AM ETGlobe Newswire
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
Press releaseApr 30, 4:01 PM ETGlobe Newswire
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
NewsApr 30, 7:11 AM ET
Earnings Scheduled For April 30, 2026
Press releaseApr 24, 7:00 AM ETGlobe Newswire
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
NewsFeb 26, 4:10 PM ET
Insights into Syndax Pharmaceuticals Q4 Earnings
Press releaseFeb 26, 4:01 PM ETGlobe Newswire
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
NewsJan 27, 1:00 PM ET
6 Analysts Assess Syndax Pharmaceuticals: What You Need To Know
Press releaseJan 12, 7:00 AM ETGlobe Newswire
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
Press releaseNov 3, 4:01 PM ETGlobe Newswire
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
NewsOct 31, 4:02 PM ET
Syndax Pharmaceuticals's Earnings Outlook
NewsOct 24, 4:07 PM ETAlex Perry
Why Is Syndax Stock Down Today?
NewsOct 16, 10:02 AM ET
Where Syndax Pharmaceuticals Stands With Analysts
NewsSep 4, 3:17 PM ETVandana Singh
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth
NewsSep 4, 10:14 AM ETAvi Kapoor
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
NewsSep 4, 8:02 AM ET
Deep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
Press releaseAug 4, 4:01 PM ETGlobe Newswire
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
NewsMay 20, 10:26 AM ETAvi Kapoor
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday
Press releaseMay 14, 9:30 AM ETGlobe Newswire
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
Press releaseMay 5, 4:01 PM ETGlobe Newswire
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
NewsApr 29, 8:10 AM ETAvi Kapoor
NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Press releaseMar 3, 7:01 AM ETGlobe Newswire
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Press releaseFeb 4, 4:05 PM ETPRNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Press releaseJan 30, 7:00 AM ETPRNewswire
Syndax Announces Participation in February Investor Conferences
Press releaseJan 15, 5:34 PM ETPRNewswire
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Press releaseJan 13, 7:00 AM ETPRNewswire
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Press releaseJan 7, 9:20 PM ETPRNewswire
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Press releaseJan 7, 7:00 AM ETPRNewswire
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Press releaseJan 3, 4:05 PM ETPRNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Press releaseDec 19, 10:37 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

Syndax Pharmaceuticals Suffers Pipeline Blow

Crude Oil Edges Higher; Citigroup Earnings Top Views

Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Why UnitedHealth Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

Earnings Scheduled For April 30, 2026

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

Insights into Syndax Pharmaceuticals Q4 Earnings

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

6 Analysts Assess Syndax Pharmaceuticals: What You Need To Know

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Syndax Pharmaceuticals's Earnings Outlook

Why Is Syndax Stock Down Today?

Where Syndax Pharmaceuticals Stands With Analysts

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth

This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Deep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation in February Investor Conferences

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors